PTC Updates On EMA Regulatory Review Timeline For AADC Deficiency Gene Therapy Program

PTC Therapeutics Inc. (PTCT), on Thursday, announced that it has completed the Scientific Advisory Group and Oral Explanation meetings for its gene therapy treatment for AADC deficiency or PTC-AADC with the Committee for Advanced Therapies or CAT.

The CAT is responsible for the scientific assessment of advanced therapies based on its expert member's assessment of the quality, safety and efficacy of the product. The CAT is scheduled to provide a draft opinion for adoption to the Committee for Medicinal Products for Human Use or CHMP in May.

If approved, PTC's AADC gene therapy would be the first marketed gene therapy directly infused into the brain, the company said.

"We are looking forward to treating patients with our gene therapy treatment for AADC deficiency," stated Stuart Peltz, Chief Executive Officer, PTC Therapeutics. "AADC deficiency is such a terrible disease and we believe that this treatment has the potential to be transformational for patients with this disorder."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Deutsche Post DHL Group were gaining around 6 percent in the morning trading in Germany after the package delivery and logistic major reported Friday higher profit and revenues in its second quarter with strong demand. Going ahead, the company confirmed its 2022 EBIT guidance of 8.0 billion euros, plus or minus 5 percent, even in consideration of a possible global economic downturn. Chinese e-commerce giant Alibaba Group Holdings Ltd. (BABA) reported Thursday net income for the first quarter halved from last year, hurt by a 1 decline in revenues and a decrease in the market prices of its equity investments in publicly-traded companies. Shares of Deutsche Lufthansa AG were gaining around 6 percent in the morning trading after the German flag carrier reported Thursday a profit in its second quarter, compared to last year's loss, benefited by surge in demand. The company also specified its outlook for the year, and now expects adjusted EBIT to be above 500 million euros for the full year of 2022, in line with current market.
Follow RTT